CHEMOMAB THERAPEUTICS LTD. - AMERICAN DEPOSITARY

Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis

18 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference

06 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

17 May 2024 07:00:00 By Nasdaq GlobeNewswire

Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

09 May 2024 07:00:01 By Nasdaq GlobeNewswire

Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

08 May 2024 07:00:00 By Nasdaq GlobeNewswire

Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference

02 May 2024 07:00:00 By Nasdaq GlobeNewswire

Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update

24 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis

18 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024

02 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

25 Mar 2024 07:06:46 By Nasdaq GlobeNewswire